Upside | ||||||
|---|---|---|---|---|---|---|
| LLY | 13.29% | aa.aa | 1,354.00 | -0.79% | 315 | |
| ASND | 10.70% | aa.aa | 256.82 | +1.33% | 1,366 | |
| NVO | 10.11% | aa.aa | 40.31 | +0.02% | 8,116 | |
| PODD | 8.49% | aa.aa | 146.51 | -6.16% | 1,758 | |
| PTGX | 6.52% | aa.aa | 132.04 | -2.38% | 1,560 | |
| SASY | 5.91% | aa.aa | 83.74 | -0.93% | 2,015 | |
| RYTM | 5.47% | aa.aa | 112.28 | +6.91% | 1,686 | |
| DAR | 3.84% | aa.aa | 50.19 | -1.01% | 2,449 | |
| BANB | 3.72% | aa.aa | 79.70 | -0.06% | 1,228 | |
| VKTX | 3.57% | aa.aa | 26.840 | +4.07% | 4,473 |
REX ETF Trust - REX Peptide ETF is an exchange traded fund launched and managed by REX Advisers, LLC. It invests in the public equity markets. The fund primarily invests in stocks of companies operating across Healthcare sector. It invests in growth and value stocks of companies operating across diversified market capitalization. The fund seeks to benchmark the performance of its portfolio against the VettaFi Peptides Index, by using full replication technique. REX ETF Trust - REX Peptide ETF was formed on October 14, 2026 and is domiciled in the United States.